Abstract:Abstract Introduction Genome-wide association studies identified the common variant rs10830963 in the MTNR1B gene (encoding melatonin receptor 1B) as a risk factor for type 2 diabetes. This sparked great interest in the role of the circadian hormone melatonin in glycemic control; however, the mechanisms underlying this association remain unclear. We investigated whether exogenous melatonin administration worsens glucose tolerance, insulin sensitivity, and beta-cell function, and whether such effect is stronger in MTNR1B G-allele risk carriers compared to non-carriers. Methods Twenty-one healthy participants of European ancestry were studied in a double-blind, randomized, cross-over trial, including ten MTNR1B risk carriers (mean age±SD, 29±10y; BMI, 24.4±2.6kg/m2; 5 women) and eleven non-carriers (32±10y; 22.5±3.0kg/m2; 3 women). Each participant underwent a highly-controlled 5-day laboratory protocol, during which they received 5mg oral melatonin or placebo in randomized order on two nonconsecutive days. Elevated circulating melatonin levels after melatonin administration were confirmed by hourly blood draw. Insulin sensitivity (SI), beta-cell function, and disposition index (DI, product of insulin secretion and sensitivity) were derived from insulin-modified frequently-sampled intravenous glucose tolerance test (FSIGT) using minimal models. Results The effect of melatonin versus placebo differed significantly between MTNR1B genotypes for glucose incremental area under the curve (iAUC180min, Pinteraction=0.005), insulin iAUC20min (Pinteraction=0.03), and C-peptide iAUC20min (Pinteraction=0.03) during FSIGT, with 11.7% increase in glucose iAUC180min (95%CI 3.1%─20.2%, P=0.03), 25.2% decrease in insulin iAUC20min (4.4%─41.2%, P=0.06), and 19.2% decrease in C-peptide iAUC20min (4.9%─31.2%, P=0.04) in carriers, without significant changes in non-carriers (n.s.). While we did not find significant effects of melatonin nor its interaction effects with MTNR1B genotype on DI and SI, first-phase insulin secretion was affected differently by melatonin in carriers and non-carriers (Pinteraction=0.001), with a 40.0% reduction in carriers (27.6%─50.3%, P< 0.0001), but no significant changes in non-carriers (n.s.). Conclusion Exogenous melatonin administration significantly impaired glucose tolerance and beta-cell function in MTNR1B risk carriers, but not in non-carriers. These data suggest that first-phase insulin secretion plays an important role in mediating the effect of melatonin on glucose control and its interaction with MTNR1B genotype. Support (if any) NIDDK Grant R01-DK102696 to FAJLS and RS, ADA fellowship 1-17-PDF-103 to JQ, and CTSA-UL1RR025758 to Harvard University and Brigham and Women’s Hospital.

Relationship Between MTNR1B (melatonin Receptor 1B Gene) Polymorphism Rs10830963 and Glucose Levels in Overweight Children and Adolescents.

Association Of The Rs10830963 Polymorphism In Mtnr1b With Fasting Glucose Levels In Chinese Children And Adolescents

A Common Variant in the MTNR1b Gene is Associated with Increased Risk of Impaired Fasting Glucose (IFG) in Youth with Obesity

Two Susceptible Diabetogenic Variants Near/in MTNR1B Are Associated with Fasting Plasma Glucose in a Han Chinese Cohort.

Association Between the Melatonin Receptor 1B Gene Polymorphism on the Risk of Type 2 Diabetes, Impaired Glucose Regulation: a Meta-Analysis.

A Common Variant in MTNR1B , Encoding Melatonin Receptor 1B, is Associated with Type 2 Diabetes and Fasting Plasma Glucose in Han Chinese Individuals

A common polymorphism rs3781637 in MTNR1B is associated with type 2 diabetes and lipids levels in Han Chinese individuals

Macronutrient-specific Effect of the MTNR1B Genotype on Lipid Levels in Response to 2 Year Weight-Loss Diets

0887 Effects of Melatonin on Glucose, Insulin, and C-Peptide Dynamics in Carriers of MTNR1B Type 2 Diabetes Risk Variant

Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk

The Association between Dietary Iron Intake, SNP of the MTNR1B rs10830963, and Glucose Metabolism in Chinese Population

Genetic Variants at PSMD3 Interact with Dietary Fat and Carbohydrate to Modulate Insulin Resistance

Evaluation of the effect of MTNR1B rs10830963 gene polymorphism on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

The Circadian Rhythm-Related MTNR1B Genotype, Gestational Weight Gain, and Postpartum Glycemic Changes.

MTNR1B Gene Variations and High Pre-Pregnancy BMI Increase Gestational Diabetes Mellitus Risk in Chinese Women.

Abstract P078: Gestational Weight Gain Modifies the Effect of the Circadian Rhythms Related MTNR1B Genotype on Postpartum Glycemic Changes: A Longitudinal Study in Women with Prior Gestational Diabetes

Relationship between glucose homeostasis and obesity in early life—a study of Italian children and adolescents

Modelling genetic risk of β-cell dysfunction in human induced pluripotent stem cells from patients carrying the MTNR1B risk variant.

Rs12970134 Near MC4R is Associated with Appetite and Beverage Intake in Overweight and Obese Children: A Family-Based Association Study in Chinese Population.

The rs7903146 Variant in the TCF7L2 Gene Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing β-Cell Function and Hepatic Insulin Sensitivity

MTNR1B-Genotyp beeinflusst glykämische Reaktion auf Kohlenhydrate